MRS may eliminate need for invasive brain biopsy

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 4
Volume 18
Issue 4

Currently, the only definitive method for telling the difference between side effects of radiation therapy for brain tumors and tumor recurrence involves a biopsy of the brain tissue, said Dr. Ewell, an assistant professor in the department of radiation oncology at the University of Arizona in Tucson. MRS has the potential to eliminate the need for this invasive procedure.

Currently, the only definitive method for telling the difference between side effects of radiation therapy for brain tumors and tumor recurrence involves a biopsy of the brain tissue, said Dr. Ewell, an assistant professor in the department of radiation oncology at the University of Arizona in Tucson. MRS has the potential to eliminate the need for this invasive procedure. The authors retrospectively studied 33 brain tumor patients that had MRS spectra taken during the course of their treatment. Choline (Cho) is a metabolite that is elevate

The authors used the ratio of Cho/NAA to predict whether a lesion represented radiation necrosis or recurrent tumor: A high ratio would indicate tumor, whereas a low ratio would indicate radiation necrosis. This metabolite ratio was successful in determining the difference in roughly 80% of the cases.

They then developed a model that would indicate which of three different clinical decisions are indicated based on the ratio: If this ratio is ≤1.1, the patient would have routine follow-up.

Related Videos
A panel of 3 experts on lung cancer
A panel of 3 experts on lung cancer
The use of CT scans may help practices adaptively plan and adjust radiotherapy courses for patients with non–small cell lung cancer.
Patients with NSCLC who have comorbidities or frailty may also be able to receive treatment with fewer toxicities via proton beam radiotherapy.
Terrence T. Sio, MD, MS, emphasizes multidisciplinary collaboration for treating patients with NSCLC who may require more than 1 type of therapy.
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Video 2 - "MARIPOSA-2 Phase 3 Study Design and Treatment Arms"
Related Content